The Food and Drug Administration (FDA) recently announced the clearance of NeuroSigma’s Monarch external Trigeminal Nerve Stimulation (eTNS) system for treating children with ADHD.
This system will be a breakthrough non-drug alternative to the numerous conventional pharmacological means of treating ADHD which include brand name drugs like Adderall, Ritalin, etc. This alternative minimizes the potentially dangerous side effects conventional ADHD drugs may cause including the risk of addiction.
Electrodes are attached to the forehead, where the electrical current will pass through the trigeminal nerve and be routed to areas of the brain regulating emotions, behavior, and the ability to focus. Results from clinical trials of this eTNS system show depression symptom reduction outcomes on par to that of certain drugs for ADHD, but without any serious adverse health risks.
For more information, click the link below: